Sales headlines hide the science that drives them, and the Eli Lilly Q3 2026 results are a good example. Lilly reported $24.4 billion of revenue on 29 October 2026, up 39%, but the more durable story is the breadth of its pipeline: a tirzepatide franchise growing quickly, an oral GLP-1 medicine already generating sales, a once-weekly insulin approved, a triple-agonist candidate reporting Phase 3 data, and newer cancer and immunology medicines gaining share. This article looks at the clinical and regulatory developments behind the quarter and separates approved medicines from investigational ones.
Eli Lilly Q3 2026 results: pipeline highlights
- Mounjaro received FDA approval to reduce cardiovascular risk in adults with type 2 diabetes.
- Onswik, a once-weekly basal insulin for type 2 diabetes, was approved.
- Retatrutide reported positive Phase 3 topline results against Ozempic 2 mg in type 2 diabetes; it is investigational.
- EloraTZP reported positive Phase 2 results in obesity with type 2 diabetes, and Phase 3 trials start in Q4 2026.
- Foundayo (orforglipron) showed cardiovascular safety in its largest, longest type 2 diabetes study.
The tirzepatide franchise in the Eli Lilly Q3 2026 results
Mounjaro generated $10.7 billion, up 65%, and Zepbound $5.4 billion, up 49%, according to the company’s earnings release. Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, a mechanism that distinguishes it from medicines acting only on GLP-1. The cardiovascular-risk approval for Mounjaro in type 2 diabetes adds to its label and may influence how doctors and insurers view it, although the release does not quantify the effect on sales.
Oral and weekly options in the Eli Lilly Q3 2026 results
Foundayo, Lilly’s oral GLP-1 medicine orforglipron, generated $184 million in the quarter, with no prior-year sales, and Lilly reported that its largest and longest type 2 diabetes study showed cardiovascular safety. Onswik, a once-weekly basal insulin, was approved for type 2 diabetes. Both reflect a trend toward less frequent or more convenient dosing, which may help adherence, though real-world evidence is still accumulating.
Retatrutide and the next generation in the Eli Lilly Q3 2026 results
Retatrutide, an investigational multi-receptor agonist, reported positive Phase 3 head-to-head topline results versus Ozempic 2 mg in type 2 diabetes. The release gives the headline conclusion but we have not seen full data, so we do not report efficacy figures. EloraTZP, another investigational medicine, reported positive Phase 2 results in obesity with type 2 diabetes. Neither is approved, and topline results are not a substitute for peer-reviewed data and regulatory review.
How to read topline trial claims in the Eli Lilly Q3 2026 results
A topline announcement is the sponsor’s first summary of a trial, usually before full analysis, peer review or regulatory scrutiny. Useful questions include: what was the primary endpoint, how large was the difference, how many patients stopped treatment because of side effects, and how long was follow-up? A positive result on a primary endpoint does not by itself show a better safety profile or benefit in every subgroup. Head-to-head designs are more informative than comparisons across separate trials, but they usually test one dose and one population. Readers should wait for the full data before drawing conclusions about retatrutide.
Cancer and immunology in the Eli Lilly Q3 2026 results
Newer medicines beyond diabetes and obesity are growing from smaller bases. Jaypirca sales were $228 million (up 59%), Ebglyss $202 million (up 59%), Kisunla $193 million (up 175%), Omvoh $114 million (up 76%) and Inluriyo $73 million. Inluriyo with Verzenio was approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, and Jaypirca gained an expanded indication for untreated CLL or SLL. Lilly says its immunology, oncology and neuroscience key products grew 100%.
Acquisitions behind the Eli Lilly Q3 2026 results
Lilly booked $4.2 billion of acquired in-process R&D charges, mainly for the AtaiBeckley and Curevo acquisitions. AtaiBeckley closed in the quarter and focuses on treatment-resistant depression and other mental health conditions. These deals show Lilly broadening beyond metabolic disease into neuropsychiatry and other areas, although the programmes involved are investigational. The release also lists a Merida Biosciences deal in autoimmune and allergic diseases, but its status is described inconsistently, so we do not state whether it has closed.
Eli Lilly Q3 2026 results: the financial frame
Revenue was up 39%, volume rose 53% and prices fell 15%. Reported EPS was $7.22 and non-GAAP EPS $7.48, both after $4.57 per share of acquired R&D charges. Full-year revenue guidance rose to $91 billion to $92 billion, and non-GAAP EPS guidance moved to $35.00 to $36.00. See our Pharmaceutical section for related reports.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Anti-Obesity Drugs Market report valued the market at USD 2.1 billion in 2022 and projected USD 8.2 billion by 2032, a CAGR of 14.6%, with North America above 68% and Asia Pacific the fastest-growing region at about 15%. It was last updated in September 2023, and Lilly’s Zepbound sales alone in one quarter exceed its 2032 figure, so it is dated. The World Health Organization describes obesity on its fact sheet.
Timeline of the Eli Lilly Q3 2026 results and pipeline
- Q3 2026: Mounjaro cardiovascular approval, Onswik approval and AtaiBeckley closing reported.
- 29 October 2026: results published.
- Q4 2026: EloraTZP Phase 3 start expected.
General background: how drug classes compete
GLP-1 medicines compete on efficacy, tolerability, dosing convenience, supply and cost. Differences between trials make direct comparison difficult, which is why head-to-head studies are valuable.
Our analysis of the Eli Lilly Q3 2026 results
In our assessment, the Eli Lilly Q3 2026 results show a company using strong tirzepatide cash flow to widen its pipeline, with the clinical proof still to come for several investigational medicines. Sales growth does not by itself measure patient benefit.
What is not disclosed in the Eli Lilly Q3 2026 results
- Full retatrutide efficacy and safety data.
- Patient numbers by medicine.
- Timelines for regulatory submissions of investigational medicines.
Risks and caveats
Investigational medicines may not be approved. Results are company-reported. This article is news reporting and not medical advice.
What to watch next
- Full retatrutide data presentation.
- EloraTZP Phase 3 start.
- Real-world Foundayo uptake.
FAQ
Is retatrutide approved?
No. It is investigational.
What is Foundayo?
Lilly’s oral GLP-1 medicine, orforglipron, which generated $184 million this quarter.
What new approvals were reported?
Mounjaro for cardiovascular risk reduction, Onswik, Inluriyo with Verzenio and an expanded Jaypirca indication.
How we reported this: we relied on the company earnings release, the Acumen Research and Consulting report cited above and public-health information. Last updated 30 October 2026. This is news reporting and not advice.
